{"success":true,"data":{"pressRelease":{"id":"68122","rtpr_id":"nGNX23dCVw","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity","author":"Globe Newswire","published_at":"2026-06-18T19:34:00.102Z","article_body":"CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=hHa-abvpic-Z3Cm4wehuCBHMT2x-_vausVkB_czlp6I5ufLgetlEg03fmGWEekQpWd5h1v-cCsq51b6UHL09mKGqpXhx-wdramxSc2TZue4=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=atlD_ij1vLdoQfbeAbLEsHWg_jTZWGqo40XrNunkx_ljjcFIAvC7kIFSrpIPNGevXIeI-d6nIH4ZTGamNrVTWqE2-WbjBUh_41QbeoClv8w=),\na diversified, vertically integrated global healthcare group, today announced\nthat its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered\nrecord revenue of over $15 million in the second quarter of 2026, representing\nan annualized run-rate of over $60 million.\n\nCosmoFarm added more than 80 new pharmacies to its distribution network during\nthe period, continuing the strong customer growth that has made it one of the\nleading pharmaceutical wholesalers in the greater Athens area.\n\nTo support this accelerating growth, Cosmos Health is increasing capital\nexpenditure at CosmoFarm, investing in new robotic automation and artificial\nintelligence systems to enhance procurement, inventory management, and order\nfulfillment. The Company is also expanding the size of the CosmoFarm facility\nto accommodate higher volumes and continued network expansion.\n\nThese investments build on CosmoFarm’s existing automated infrastructure,\nincluding ROWA and SSI SCHÄFER A-frame robotic systems, which have driven\nimprovements in operational efficiency, unit economics, and profitability per\ncustomer.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"CosmoFarm’s record second\nquarter marks an important milestone, with revenue reaching an annualized\nrun-rate of over $60 million. The addition of over 80 new pharmacies reflects\nthe strength of our distribution platform and the trust of our growing\ncustomer base. By investing further in robotic automation, artificial\nintelligence, and expanded facility capacity, we are positioning CosmoFarm to\nsustain this momentum, improve margins, and continue scaling profitably.”\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=P3sLqkKK0HDeAEs2rkYb2U4KdVlqwtK74N9LpPO13No3sOJzGq-0ksKTgwOIr5JeRItvGS_UKp73Q3Dz5OH4mKN2SdzI5ci6SKhhKNrfCd6K-T2TWRNFbQ6V5svlA8HD)\nand X\n(https://www.globenewswire.com/Tracker?data=kR-NXx3JjJNGuSIBZKOyTUXwAPI6UrAEG-vB0orzfuK-TZlb01TYHKC9azQYwJemfWzP7OUT80DozxqYVhqZrGsPCo7IjlRfVLa7gI6b75A=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX23dCVw","title":"CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity","author":"Globe Newswire","ticker":"COSM","created":"2026-06-18T19:34:00.102Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=hHa-abvpic-Z3Cm4wehuCBHMT2x-_vausVkB_czlp6I5ufLgetlEg03fmGWEekQpWd5h1v-cCsq51b6UHL09mKGqpXhx-wdramxSc2TZue4=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=atlD_ij1vLdoQfbeAbLEsHWg_jTZWGqo40XrNunkx_ljjcFIAvC7kIFSrpIPNGevXIeI-d6nIH4ZTGamNrVTWqE2-WbjBUh_41QbeoClv8w=),\na diversified, vertically integrated global healthcare group, today announced\nthat its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered\nrecord revenue of over $15 million in the second quarter of 2026, representing\nan annualized run-rate of over $60 million.\n\nCosmoFarm added more than 80 new pharmacies to its distribution network during\nthe period, continuing the strong customer growth that has made it one of the\nleading pharmaceutical wholesalers in the greater Athens area.\n\nTo support this accelerating growth, Cosmos Health is increasing capital\nexpenditure at CosmoFarm, investing in new robotic automation and artificial\nintelligence systems to enhance procurement, inventory management, and order\nfulfillment. The Company is also expanding the size of the CosmoFarm facility\nto accommodate higher volumes and continued network expansion.\n\nThese investments build on CosmoFarm’s existing automated infrastructure,\nincluding ROWA and SSI SCHÄFER A-frame robotic systems, which have driven\nimprovements in operational efficiency, unit economics, and profitability per\ncustomer.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"CosmoFarm’s record second\nquarter marks an important milestone, with revenue reaching an annualized\nrun-rate of over $60 million. The addition of over 80 new pharmacies reflects\nthe strength of our distribution platform and the trust of our growing\ncustomer base. By investing further in robotic automation, artificial\nintelligence, and expanded facility capacity, we are positioning CosmoFarm to\nsustain this momentum, improve margins, and continue scaling profitably.”\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=P3sLqkKK0HDeAEs2rkYb2U4KdVlqwtK74N9LpPO13No3sOJzGq-0ksKTgwOIr5JeRItvGS_UKp73Q3Dz5OH4mKN2SdzI5ci6SKhhKNrfCd6K-T2TWRNFbQ6V5svlA8HD)\nand X\n(https://www.globenewswire.com/Tracker?data=kR-NXx3JjJNGuSIBZKOyTUXwAPI6UrAEG-vB0orzfuK-TZlb01TYHKC9azQYwJemfWzP7OUT80DozxqYVhqZrGsPCo7IjlRfVLa7gI6b75A=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-18T19:34:00.141217974Z","server_sent_at_ms":1781811240141},"received_at":"2026-06-18T19:34:00.203Z","source_url":null},"analysis":{"id":"57534","press_release_id":"68122","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Cosmos Health's subsidiary CosmoFarm achieved record Q2 2026 revenue exceeding $15 million, which equates to an annualized run-rate of over $60 million.\n\nThe subsidiary expanded its distribution network by adding more than 80 new pharmacies, reinforcing its position as a leading wholesaler in the Athens region.\n\nTo sustain this growth, the company is increasing capital expenditures on robotic automation and AI while expanding its facility capacity to improve margins and unit economics.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"CosmoFarm hits $60M annualized run-rate, accelerates capacity expansion."},"keyFigures":{"revenue":">$15 million","customDimensions":{"new_pharmacies":">80","annualized_run_rate":">$60 million"}},"quotedText":"CosmoFarm’s record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over $60 million. The addition of over 80 new pharmacies reflects the strength of our distribution platform and the trust of our growing customer base. By investing further in robotic automation, artificial intelligence, and expanded facility capacity, we are positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["ROWA","SSI SCHÄFER A-frame robotic systems","Sky Premium Life®","Mediterranation®","bio-bebe®","C-Sept®","C-Scrub®"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"CosmoFarm S.A.","relationship":"subsidiary"},{"name":"ROWA","relationship":"vendor"},{"name":"SSI SCHÄFER","relationship":"vendor"}],"dollarAmounts":[{"amount":"$15 million","context":"Q2 2026 revenue"},{"amount":"$60 million","context":"annualized revenue run-rate"}]},"materialImpact":{"score":2,"reasoning":"Record quarterly revenue and significant customer acquisition for a subsidiary, signaling robust operational momentum. However, this is an operational update rather than a full earnings report or a binary event, limiting immediate market-moving potential."},"tickerRelevance":{"others":[],"primary":"COSM"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"operational_milestone","sectorWeight":"health_care"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Cosmos Health's subsidiary CosmoFarm achieved record Q2 2026 revenue exceeding $15 million, which equates to an annualized run-rate of over $60 million.\n\nThe subsidiary expanded its distribution network by adding more than 80 new pharmacies, reinforcing its position as a leading wholesaler in the Athens region.\n\nTo sustain this growth, the company is increasing capital expenditures on robotic automation and AI while expanding its facility capacity to improve margins and unit economics.","key_figures":{"revenue":">$15 million","customDimensions":{"new_pharmacies":">80","annualized_run_rate":">$60 million"}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["ROWA","SSI SCHÄFER A-frame robotic systems","Sky Premium Life®","Mediterranation®","bio-bebe®","C-Sept®","C-Scrub®"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"CosmoFarm S.A.","relationship":"subsidiary"},{"name":"ROWA","relationship":"vendor"},{"name":"SSI SCHÄFER","relationship":"vendor"}],"dollarAmounts":[{"amount":"$15 million","context":"Q2 2026 revenue"},{"amount":"$60 million","context":"annualized revenue run-rate"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-18T19:35:38.070Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"operational_milestone","sectorWeight":"health_care"}},"durationMs":97851,"modelName":"george-droid-qwen-72b"}}